These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 23349989)

  • 1. A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models.
    Zhang H; Berel D; Wang Y; Li P; Bhowmick NA; Figlin RA; Kim HL
    PLoS One; 2013; 8(1):e54918. PubMed ID: 23349989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acquired resistance to temsirolimus in human renal cell carcinoma cells is mediated by the constitutive activation of signal transduction pathways through mTORC2.
    Harada K; Miyake H; Kumano M; Fujisawa M
    Br J Cancer; 2013 Oct; 109(9):2389-95. PubMed ID: 24091619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endothelial Cell mTOR Complex-2 Regulates Sprouting Angiogenesis.
    Farhan MA; Carmine-Simmen K; Lewis JD; Moore RB; Murray AG
    PLoS One; 2015; 10(8):e0135245. PubMed ID: 26295809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
    Serova M; de Gramont A; Tijeras-Raballand A; Dos Santos C; Riveiro ME; Slimane K; Faivre S; Raymond E
    Cancer Chemother Pharmacol; 2013 May; 71(5):1297-307. PubMed ID: 23479136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological inhibition of mTORC1 but not mTORC2 protects against human disc cellular apoptosis, senescence, and extracellular matrix catabolism through Akt and autophagy induction.
    Kakiuchi Y; Yurube T; Kakutani K; Takada T; Ito M; Takeoka Y; Kanda Y; Miyazaki S; Kuroda R; Nishida K
    Osteoarthritis Cartilage; 2019 Jun; 27(6):965-976. PubMed ID: 30716534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
    Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
    Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KU0063794, a Dual mTORC1 and mTORC2 Inhibitor, Reduces Neural Tissue Damage and Locomotor Impairment After Spinal Cord Injury in Mice.
    Cordaro M; Paterniti I; Siracusa R; Impellizzeri D; Esposito E; Cuzzocrea S
    Mol Neurobiol; 2017 May; 54(4):2415-2427. PubMed ID: 26960330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition.
    Ito H; Ichiyanagi O; Naito S; Bilim VN; Tomita Y; Kato T; Nagaoka A; Tsuchiya N
    BMC Cancer; 2016 Jul; 16():393. PubMed ID: 27387559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapamycin attenuates BAFF-extended proliferation and survival via disruption of mTORC1/2 signaling in normal and neoplastic B-lymphoid cells.
    Zeng Q; Qin S; Zhang H; Liu B; Qin J; Wang X; Zhang R; Liu C; Dong X; Zhang S; Huang S; Chen L
    J Cell Physiol; 2018 Jan; 233(1):516-529. PubMed ID: 28300280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RhoA modulates signaling through the mechanistic target of rapamycin complex 1 (mTORC1) in mammalian cells.
    Gordon BS; Kazi AA; Coleman CS; Dennis MD; Chau V; Jefferson LS; Kimball SR
    Cell Signal; 2014 Mar; 26(3):461-7. PubMed ID: 24316235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feedback loops blockade potentiates apoptosis induction and antitumor activity of a novel AKT inhibitor DC120 in human liver cancer.
    Yang F; Deng R; Qian XJ; Chang SH; Wu XQ; Qin J; Feng GK; Ding K; Zhu XF
    Cell Death Dis; 2014 Mar; 5(3):e1114. PubMed ID: 24625973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin.
    Huang Y; Xi Q; Chen Y; Wang J; Peng P; Xia S; Yu S
    Anticancer Drugs; 2013 Oct; 24(9):889-98. PubMed ID: 23838676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular tumors have increased p70 S6-kinase activation and are inhibited by topical rapamycin.
    Du W; Gerald D; Perruzzi CA; Rodriguez-Waitkus P; Enayati L; Krishnan B; Edmonds J; Hochman ML; Lev DC; Phung TL
    Lab Invest; 2013 Oct; 93(10):1115-27. PubMed ID: 23938603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts.
    Ingels A; Zhao H; Thong AE; Saar M; Valta MP; Nolley R; Santos J; Peehl DM
    Int J Cancer; 2014 May; 134(10):2322-9. PubMed ID: 24243565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The synergistic inhibition of breast cancer proliferation by combined treatment with 4EGI-1 and MK2206.
    Wang H; Huang F; Wang J; Wang P; Lv W; Hong L; Li S; Zhou J
    Cell Cycle; 2015; 14(2):232-42. PubMed ID: 25607647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concurrent inhibition of mTORC1 and mTORC2 by WYE-687 inhibits renal cell carcinoma cell growth in vitro and in vivo.
    Pan XD; Gu DH; Mao JH; Zhu H; Chen X; Zheng B; Shan Y
    PLoS One; 2017; 12(3):e0172555. PubMed ID: 28257457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
    Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J
    PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules.
    Guichard SM; Curwen J; Bihani T; D'Cruz CM; Yates JW; Grondine M; Howard Z; Davies BR; Bigley G; Klinowska T; Pike KG; Pass M; Chresta CM; Polanska UM; McEwen R; Delpuech O; Green S; Cosulich SC
    Mol Cancer Ther; 2015 Nov; 14(11):2508-18. PubMed ID: 26358751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells.
    Chen BW; Chen W; Liang H; Liu H; Liang C; Zhi X; Hu LQ; Yu XZ; Wei T; Ma T; Xue F; Zheng L; Zhao B; Feng XH; Bai XL; Liang TB
    Mol Cancer Ther; 2015 Aug; 14(8):1805-15. PubMed ID: 26026051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical efficacy of dual mTORC1/2 inhibitor AZD8055 in renal cell carcinoma harboring a TFE3 gene fusion.
    Kauffman EC; Lang M; Rais-Bahrami S; Gupta GN; Wei D; Yang Y; Sourbier C; Srinivasan R
    BMC Cancer; 2019 Sep; 19(1):917. PubMed ID: 31519159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.